Dr. Parameswaren Venugopal, M.D.
Hematology (Hematology (Internal Medicine) Physician)
1725 W Harrison St, Suite 1010
Chicago, IL 60612
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 50
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 617
Licensed in Illinois since 1994, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
IL license 036088953 (first issued 1994; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Rush University Medical Center Chicago, IL
- Rush Oak PArk Hospital Oak PArk, IL
Medical groups
- Rush University Medical Group (1,551 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 617
- Services billed
- 1,166
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 552 | 428 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 206 | 63 |
| Established patient office or other outpatient visit, 30-39 minutes | 185 | 151 |
| New patient office or other outpatient visit, 60-74 minutes | 176 | 176 |
| Telephone medical discussion with physician, 21-30 minutes | 79 | 65 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 26 | 25 |
| Established patient office or other outpatient visit, 20-29 minutes | 14 | 13 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Revlimid (lenalidomide) | 544 |
| Acyclovir Other prescribers in Chicago, IL | 200 |
| Brukinsa (zanubrutinib) | 129 |
| Pomalyst (pomalidomide) | 109 |
| Ondansetron Hcl Other prescribers in Chicago, IL | 77 |
| Allopurinol Other prescribers in Chicago, IL | 74 |
| Venclexta (venetoclax) | 65 |
| Imbruvica (ibrutinib) | 57 |
| Prednisone Other prescribers in Chicago, IL | 48 |
| Calquence (acalabrutinib maleate) | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $3,056 in total to this clinician.
| Beone Medicines USA, Inc. | $2,250 |
|---|---|
| AbbVie Inc. | $725 |
| Genmab U.S., Inc. | $80.54 |
| Compensation for services other than consulting (speaking, faculty) | $2,250 |
|---|---|
| Consulting Fee | $725 |
| Food and Beverage | $80.54 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Beone Medicines USA, Inc. Jun 26, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $2,250 |
| AbbVie Inc. Feb 10, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $363 |
| AbbVie Inc. Sep 11, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $363 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $108,391 in research payments for these studies, mostly to the institutions running them.
- Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
AbbVie Inc. · Completed · NCT02947347 - A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT03888105 - INCB50465-801, Ph2, Roll-Over Study
Incyte Corporation - Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.